T-518

T-518 is an orally active, BBB-penetrant and potent DFMO-based HDAC6 inhibitor with high selectivity (IC50 = 36 nM) . T-518 improves axonal transport. T-518 ameliorates object recognition deficit. T-518 can be studied in research for Alzheimer’s disease and tauopathy[1][2].

Product Specifications

CAS Number

[2276680-91-0]

UNSPSC

12352005

Target

HDAC; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/t-518.html

Purity

98.40

Solubility

10 mM in DMSO

Smiles

O=C(C(F)(F)C(F)(F)F)N[C@H]1[C@H](N2CC3=NC=C(C4=NN=C(C(F)F)O4)C=C3C2=O)CCCC1

Molecular Formula

C19H16F7N5O3

Molecular Weight

495.35

References & Citations

[1]Onishi T, et al. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice. Sci Rep. 2021 Jul 29;11 (1) :15423. |[2]König B, et al. 2- (Difluoromethyl) -1, 3, 4-oxadiazoles: The Future of Selective Histone Deacetylase 6 Modulation?[J]. ACS Pharmacology & Translational Science, 2024.